专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005102287A2 Pharmaceutical compositions for acute glucocorticoid therapy 审中-公开
标题翻译：急性糖皮质激素治疗药物组合物
公开(公告)号：WO2005102287A2
公开(公告)日：2005-11-03
申请号：PCT/EP2005/004399
申请日：2005-04-21
申请人： DUOCORT AB , SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
发明人： SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
IPC分类号： A61K9/20
CPC分类号： A61K9/0095 , A61K9/006 , A61K9/2018 , A61K9/5078 , A61K9/7007 , A61K31/00 , A61K31/573
摘要： The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid
摘要翻译：本发明涉及用于需要急性糖皮质激素治疗的急性紧急情况下的含糖皮质激素的药物组合物或试剂盒。值得注意的是，本发明涉及被设计为由医院外的非医学训练者或其他医学或临床环境施用的药物组合物和试剂盒。本发明还涉及通过提供糖皮质激素的快速起效来治疗需要急性糖皮质激素治疗的疾病的方法

2. 发明申请

WO2005102271A2 PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY 审中-公开
标题翻译：用于葡萄糖替代治疗的药物组合物
公开(公告)号：WO2005102271A2
公开(公告)日：2005-11-03
申请号：PCT/EP2005/004400
申请日：2005-04-21
申请人： DUOCORT AB , SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
发明人： SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
IPC分类号： A61K9/00
CPC分类号： A61K31/573 , A61K9/2031 , A61K9/209 , A61K9/28
摘要： The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents. The invention also relates to a kit comprising a first and a second component, the first component designed to release one or more glucocorticoids substantially immediately and the second component is designed to release one or more glucocorticoids over an extended period of time of at least 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. In another aspect the invention relates to the use of a first and a second amount of one or more glucocorticoids for the preparation of a pharmaceutical composition or kit for the treatment of a glucocorticoid deficiency disorder.
摘要翻译：本发明涉及糖皮质激素替代疗法，并且提供药物组合物和试剂盒，其设计用于将一种或多种糖皮质激素递送至有需要的受试者，其方式使得糖皮质激素的血清水平基本上模拟健康受试者在临床相关期间的时间。药物组合物包含一种或多种糖皮质激素，其中一种或多种糖皮质激素的第一部分基本上立即释放，并且一种或多种糖皮质激素的第二部分在至少约8小时的延长时间内释放，表示为氢化可的松当量的第一部分的一种或多种糖皮质激素在总氢化可的松当量的约15至约50％的范围内。本发明还涉及包含第一和第二组分的试剂盒，第一组分被设计成基本上立即释放一种或多种糖皮质激素，并且第二组分被设计成在至少8小时的延长的时间段内释放一种或多种糖皮质激素。本发明还涉及治疗需要糖皮质激素治疗的疾病的方法，例如具有糖皮质激素缺乏症的受试者。在另一方面，本发明涉及第一和第二量的一种或多种糖皮质激素在制备用于治疗糖皮质激素缺乏症的药物组合物或试剂盒中的用途。

3. 发明申请

WO2010115615A1 IMPROVED GLUCOCORTICOID THERAPY 审中-公开
标题翻译：改善GLUCOCORTICOID治疗
公开(公告)号：WO2010115615A1
公开(公告)日：2010-10-14
申请号：PCT/EP2010/002178
申请日：2010-04-07
申请人： DUOCORT PHARMA AB , LENNERNÄS, Hans , JOHNSSON, Jörgen , HEDNER, Thomas , JOHANNSSON, Gudmundur , SKRTIC, Stanko
发明人： LENNERNÄS, Hans , JOHNSSON, Jörgen , HEDNER, Thomas , JOHANNSSON, Gudmundur , SKRTIC, Stanko
IPC分类号： A61K31/573 , A61P5/44
CPC分类号： A61K31/573 , A61K9/28 , A61K47/38
摘要： The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects.
摘要翻译：本发明涉及改善的糖皮质激素治疗以及治疗或预防由于内源性糖皮质激素分泌模式减少或破坏引起的许多病症。本发明基于以下发现：产生特异性血清皮质醇时间曲线，其模拟在患有糖皮质激素分泌模式减少或破坏的受试者中健康受试者的皮质醇的昼夜节律，从而有助于减少副作用。

4. 发明申请

WO2011144327A1 POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS 审中-公开
标题翻译：基于GLUCOCORTICOID的组合物的生物学和药理学
公开(公告)号：WO2011144327A1
公开(公告)日：2011-11-24
申请号：PCT/EP2011/002466
申请日：2011-05-18
申请人： DUOCORT PHARMA AB , HEDNER, Thomas , SIMONSSON, Ulrika, Sigrida, Helena , JOHANNSSON, Gudmundur , LENNERNÄS, Hans , SKRTIC, Stanko
发明人： HEDNER, Thomas , SIMONSSON, Ulrika, Sigrida, Helena , JOHANNSSON, Gudmundur , LENNERNÄS, Hans , SKRTIC, Stanko
IPC分类号： A61K31/573 , A61P5/44 , A61K9/00
CPC分类号： A61K31/573 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K9/28 , G01N33/743
摘要： The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.
摘要翻译：本发明涉及一种在糖皮质激素替代疗法中施用基于糖皮质激素的组合物的改进方法，其使得能够基于客观的方案进行给药，从而能够对糖皮质激素进行正确的个体给药，从而导致优化的个体替代疗法，从而改善临时患者的长期结果或慢性肾上腺功能不全。

5. 发明申请

WO2008092656A1 USE OF FIBRINOGEN AS A PROPHYLACTIC TREATMENT TO PREVENT BLEEDING DURING AND AFTER SURGERY AND AS A BIOMARKER TO IDENTIFY PATIENT WITH AN INCREASED RISK FOR EXCESSIVE BLEEDING AND BLOOD TRANSFUSION 审中-公开
标题翻译：使用纤维蛋白作为预防治疗，以防止手术后和作为生物标志物鉴定出患者出现过度出血和血液转移增加风险的预防手术
公开(公告)号：WO2008092656A1
公开(公告)日：2008-08-07
申请号：PCT/EP2008/000710
申请日：2008-01-30
申请人： JEPPSSON, Anders , SKRTIC, Stanko , BRUCE, Lennart , JOHNSSON, Jörgen , HEDNER, Thomas
发明人： JEPPSSON, Anders , SKRTIC, Stanko , BRUCE, Lennart , JOHNSSON, Jörgen , HEDNER, Thomas
IPC分类号： A61K38/36
CPC分类号： A61K38/363 , A61K38/11 , A61K38/57 , A61K2300/00
摘要： The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve.
摘要翻译：本发明提供一种预防接受手术的受试者的周围和术后出血的方法，特别是具有等于或高于正常范围的术前纤维蛋白原血浆水平的受试者。该方法包括以导致纤维蛋白原血浆水平为约1.0g / L的量向受试者施用具有纤维蛋白原样活性的物质。本发明还提供了一种用于确定术前纤维蛋白原血浆水平等于或高于术后出血正常范围的受试者的风险的方法。此外，本发明提供了在具有等于或高于正常范围的术前纤维蛋白原血浆水平的受试者经受外科手术后预测血液或血浆输血的必要性的手段。手段包括在手术前测量受试者的纤维蛋白原水平，并将该水平与风险曲线进行比较。

6. 发明申请

WO2018229083A1 COMPOUNDS FOR USE AS RADIOLIGANDS 审中-公开
公开(公告)号：WO2018229083A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065562
申请日：2018-06-12
申请人： ASTRAZENECA AB , JOHNSTRÖM, Peter , SCHOU, Magnus , CSELÉNYI, Zsolt , SÖRHEDE-WINZELL, Maria , SKRTIC, Stanko , JOHANSSON, Lars Olof Mikael
发明人： JOHNSTRÖM, Peter , SCHOU, Magnus , CSELÉNYI, Zsolt , SÖRHEDE-WINZELL, Maria , SKRTIC, Stanko , JOHANSSON, Lars Olof Mikael
IPC分类号： C07C313/02 , C07C317/22 , C07C323/20 , A61K51/04
CPC分类号： A61K51/0402 , C07B59/001 , C07B2200/05 , C07C313/02 , C07C317/22 , C07C323/20
摘要： The present invention relates to compounds, in particular those of formula (I) and formula (II) described herein, or pharmaceutically acceptable salts or solvates thereof, which may be used as radioligands in in vitro, ex vivo and in vivo beta cell imaging (BMI) methods, in particular as GPR44 radioligands for visualizing pancreatic beta cells. The invention also relates to a process for preparing the radioligands of formula (I) or formula (II), as well as compounds of formula (III), (IV) and (V) described herein, or pharmaceutically acceptable salts or solvates thereof, useful in the preparation of the compounds of formula (I) and formula (II).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式